At the core of Winclove’s probiotic development process is our goal to unlock the microbiome’s potential. All our research and development is focused on applying microbiome science to host biology, aimed to discover and formulate more effective therapeutic options for chronic diseases. To give you some insight, these are the next-generation probiotics that we have introduced in 2016.
Allergies are on the rise, and with that the prevalence of food allergies and intolerances. In Westernized countries about 15-20% of the people may suffer from a form of food intolerance.
Lactose intolerance is one of the target areas where the evidence for probiotics is strongest, according to recent review articles (Sanders, 2013). With this knowledge in mind, we are developing a multispecies, probiotic formulation for people suffering from this type of food hypersensitivity. This probiotic therapy is composed of strains that are selected specifically for their in vitro β-galactosidase production, their in vitro possibility to strengthen gut barrier function, and their capacity to exert a beneficial influence on the immune system. We have planned clinical studies to substantiate the evidence for the formulation in lactose intolerant patients.
Urinary tract infections
Urinary tract infection (UTI) is a common bacterial infection of the urinary tract. One third of all women experience once in their lifetime a UTI. A recurrent UTI (rUTI) is defined as two episodes of UTI in six months or three or more in one year. Between 35% to 53% of women treated for UTIs will experience a rUTI within twelve months.
Studies have shown that the urinary tract has its own unique microbial community. When the urinary microbiota is disturbed, pathogens can take over and cause a UTI. The standard treatment of these infections is antibiotics. However, antibiotics can’t support the host and are therefore unable to help mitigate the risk of recurrent infections. Additionally, antibiotics come with many negative side effects such as antibiotic resistance.
Using probiotics to restore the urinary microbiome offers a natural, healthy alternative solution in the treatment of rUTIs. Probiotic therapies work against uropathogens as follows;
- They compete with pathogens for attachment sites and nutrients.
- They produce antibacterial agents such as bacteriocins and hydrogen peroxide.
- They acidify the environment through lactic acid production, to reduce pathogen growth.
- They stimulate and balance the host’s immune system and inhibit the adhesion of uropathogens to the surface of cells.
Winclove is developing a probiotic formulations that will not only focus on the inhibition of uropathogens within the bladder or urinary tract, but also in the gut and vagina. This will be achieved through a strategic and complimentary combination of probiotics and functional ingredients.
The human intestinal microbiome is continuously subject to a plethora of challenges such as host-immune responses, nutritional variation and the invasion of pathogenic species. Dysbiosis (a disruption of the normal microbial balance) is the result and may lead to a variety of disorders.
Resilience is defined in two ways: first, it’s the amount of stress or challenges a person can tolerate before he or she enters a diseased state, and second it’s the speed at which a person recovers from these challenges and thus ‘springs’ back to a normal, healthy state. This applies very much to the microbiome as well. The resilience of microbiota is determined by two important factors: richness and diversity – or: the number and different types of bacterial species in a given system.
To increase the tolerance for disturbances, Winclove is developing a new formulation: RESILIENCE. It is specifically designed to enhance the richness and diversity of the gut microbiome. Increased resilience will reduce the risk of getting sick, while also promoting faster recovery in case one does. The RESILIENCE formula will contain a large variety of strains, including Lactobacilli, Bifidobacteria, Lactococci, Pediococci, Probionibacteria and the yeast Saccharomyces boulardii.
Ear, nose and throat infections
Infections like tonsillitis and otitis media are often caused by a dysbalance in the local microbiome. The standard treatment for this is administering antibiotics. The problem with this approach is that antibiotics not only kill the pathogens, but also the commensal bacteria that offer protection against these pathogens. The result is a cycle of recurrent infections that require antibiotics every time.
To break this cycle, we are developing probiotics that supports the natural microbiota and through this offers protection against returning pathogens. This formulation should be administered directly after the first treatment with antibiotics. This ensures that the normal, beneficial microbiota develop quickly, creating an effective line of defence against recurring pathogens.
Winclove recently bought ten probiotic bacterial strains with accompanying patent from the Swiss company Probac. The acquisition of this patent allows us to bring a targeted alternative probiotic solution to market in the near future.